List of Excipients in Branded Drug AZELEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Almirall LLC	AZELEX	azelaic acid	16110-869	BENZOIC ACID
Almirall LLC	AZELEX	azelaic acid	16110-869	CETEARYL ETHYLHEXANOATE
Almirall LLC	AZELEX	azelaic acid	16110-869	CETOSTEARYL ALCOHOL
Almirall LLC	AZELEX	azelaic acid	16110-869	GLYCERIN
Almirall LLC	AZELEX	azelaic acid	16110-869	GLYCERYL MONO AND DIPALMITOSTEARATE
Almirall LLC	AZELEX	azelaic acid	16110-869	GLYCERYL MONOSTEARATE

Azelex Excipient Strategy and Commercial Opportunities: Azelaic Acid 20% Cream

Last updated: August 2, 2026

Azelex is a prescription topical cream containing 20% azelaic acid for mild-to-moderate inflammatory acne vulgaris. Its commercial opportunity is less dependent on molecule-level patent protection than on formulation performance, tolerability, manufacturing cost, dermatology positioning, and differentiated generic or branded-generic delivery systems. The product’s relatively simple cream composition creates potential for lower-cost generic entry, while also leaving room for improved vehicles, preservative systems, sensory properties, and adherence-oriented products.

What is Azelex and what does it contain?

Azelex is a topical azelaic acid cream approved in the United States for the treatment of mild-to-moderate inflammatory acne vulgaris in adults and adolescents aged 12 years and older. The labeled strength is 20% azelaic acid by weight.[1]

Azelaic acid is a naturally occurring dicarboxylic acid with antimicrobial, keratinization-normalizing, and anti-inflammatory activity. It is used across acne, rosacea, post-inflammatory hyperpigmentation, and melasma markets, although the Azelex label is directed to acne vulgaris.

The Azelex cream contains the following inactive ingredients:

Excipient	Formulation role
Benzoic acid	Preservative and pH control
Glycerin	Humectant
Glyceryl stearate	Emulsifier and consistency agent
Isopropyl myristate	Emollient and skin-penetration aid
Polyethylene glycol	Solvent and humectant contribution
Purified water	Aqueous vehicle
Stearyl alcohol	Thickener, emollient and stabilizer

The formulation is an oil-in-water cream designed to disperse a high concentration of poorly water-soluble azelaic acid. The key technical challenge is maintaining uniform drug distribution, acceptable skin feel, chemical stability, and low irritation at a 20% drug load.

What formulation characteristics make Azelex commercially important?

Azelex’s excipient system addresses three core formulation problems: azelaic acid solubility, cream stability, and patient tolerability.

Azelaic acid has limited aqueous solubility. A conventional aqueous cream therefore requires controlled particle size, effective dispersion, and sufficient emulsification. Glyceryl stearate, stearyl alcohol, isopropyl myristate, polyethylene glycol and glycerin collectively support the semisolid vehicle.

The formulation also has commercial limitations:

• High drug loading can create a gritty or uneven skin texture.
• Azelaic acid can cause burning, stinging, itching, dryness and erythema.
• Cream residue and poor spreadability can reduce adherence.
• Benzoic acid may create tolerability concerns for sensitive skin.
• Isopropyl myristate can affect sensory attributes and may be viewed negatively in acne-prone formulations by some consumers.
• The product requires robust control of particle size and suspension uniformity.

These limitations create opportunities for competing formulations that retain 20% azelaic acid while improving elegance, tolerability, absorption, or packaging.

What patents protect Azelex?

Azelex is based on an old active pharmaceutical ingredient, and the principal commercial barriers are unlikely to come from basic azelaic acid composition-of-matter protection. Publicly available FDA product information identifies Azelex as a 20% azelaic acid cream approved under NDA 019978.[1]

A patent review should separate four categories:

Protection category	Azelex commercial relevance
Azelaic acid composition patents	Low practical relevance because the active ingredient is long established
Azelex-specific cream formulation patents	Requires confirmation through current Orange Book and patent databases
Method-of-use patents	Potentially relevant for acne, rosacea, hyperpigmentation or related indications
Manufacturing and process patents	Potentially relevant if they cover particle size, dispersion, homogenization or scale-up controls

The FDA Orange Book should be checked for currently listed patents and use codes associated with NDA 019978.[2] A formulation patent can create a meaningful barrier only if it is listed, enforceable, and relevant to the proposed generic product. Unlisted manufacturing patents may still create technical or litigation risk, but they do not necessarily block an abbreviated new drug application.

No reliable commercial conclusion should be drawn from the existence of historical azelaic acid patents alone. Patent expiration, ownership, terminal disclaimers, reexamination history and Orange Book listing status must be assessed at the individual patent level.

When does Azelex lose exclusivity?

Azelex’s regulatory exclusivity period has long expired. The product was approved in the 1990s, and the five-year new chemical entity exclusivity period and three-year new clinical investigation exclusivity period are no longer relevant to current market entry.[1,3]

The principal remaining exclusivity question is patent-based. For an old topical product, generic entry depends on:

1. Whether any patents remain listed in the Orange Book.
2. Whether a generic applicant submits a Paragraph III or Paragraph IV certification.
3. Whether the reference product sponsor files patent litigation within the statutory period.
4. Whether the formulation can be designed around any enforceable claims.
5. Whether the FDA approves the ANDA after resolving regulatory exclusivity and patent-related requirements.

Because topical creams may have complex formulation and bioequivalence requirements, practical entry can remain difficult even when statutory exclusivity has expired.

What is the Orange Book status of Azelex?

Azelex is an FDA-approved prescription drug product listed in the Orange Book under its azelaic acid cream product information.[2] The Orange Book is the authoritative source for current reference-product status, therapeutic equivalence evaluations, patent listings and exclusivity codes.

For commercial diligence, the relevant questions are:

• Is Azelex currently designated as the reference listed drug?
• Are any patents listed against the 20% cream?
• Are there approved therapeutically equivalent generic products?
• Are any patents associated with method-of-use codes rather than the cream formulation?
• Has the reference product sponsor changed through acquisition, licensing or transfer?

The Orange Book listing should be reconciled with FDA’s Drugs@FDA database and current DailyMed labeling because product ownership, labeler information and marketing status can change over time.[1,2,4]

Which companies are challenging Azelex with generic products?

Azelaic acid products have historically been marketed by multiple companies, including manufacturers and distributors of generic azelaic acid cream. The competitive field is broader than Azelex alone because azelaic acid is also sold through products for rosacea and through nonprescription cosmetic channels.

A generic applicant may pursue:

• A conventional 20% azelaic acid cream.
• A cream with a different preservative system.
• A gel or foam dosage form, if supported by a separate regulatory pathway.
• A product with lower sensory irritation.
• A formulation designed for acne, rosacea or hyperpigmentation.

A Paragraph IV challenge would be meaningful only if an applicable Orange Book patent remained listed. With an old topical product, the more likely commercial pressure is paragraph III or non-infringing generic development rather than a high-value patent challenge.

How strong is the Azelex patent estate?

The Azelex patent estate appears strategically weaker than the estate surrounding newer topical products because:

• Azelaic acid is an established active ingredient.
• The product was approved decades ago.
• Regulatory exclusivity has expired.
• The formulation uses conventional cream excipients.
• Generic developers can potentially alter excipient ratios while maintaining the same active strength and dosage form.

The main residual strength would come from narrow formulation claims, specific particle-size distributions, manufacturing controls, or clinically demonstrated performance characteristics. Such claims are harder to enforce against a generic unless they are listed and clearly practiced by the accused product.

From an investment perspective, Azelex is better analyzed as a formulation and commercial execution opportunity than as a conventional patent-protected asset.

What excipient strategies could improve Azelex?

Low-irritation cream reformulation

A reformulated product could reduce or remove excipients associated with irritation or undesirable sensory properties while preserving the 20% azelaic acid concentration.

Potential changes include:

• Replacing benzoic acid with an alternative preservative system.
• Using a less greasy emollient than isopropyl myristate.
• Reducing fatty alcohol content to improve spreadability.
• Adjusting pH to improve comfort and stability.
• Adding barrier-supportive excipients such as ceramide-compatible lipids or skin-conditioning agents.

Any change would require evaluation of preservative effectiveness, microbial limits, stability, particle uniformity, rheology and skin compatibility.

Improved suspension and particle-size control

Azelaic acid’s physical form is central to product performance. A controlled particle-size distribution can improve:

• Dose uniformity.
• Smoothness during application.
• Suspension stability.
• Release from the cream.
• Reproducibility between manufacturing lots.

A differentiated formulation may use micronized azelaic acid, controlled milling, wetting agents or structured emulsions. These changes can support a proprietary formulation position even when the active ingredient itself is unprotected.

Gel, foam and emulgel systems

A gel or emulgel may provide a lighter skin feel than a conventional cream. A foam could improve application to large or hairy areas, but it would introduce manufacturing, packaging and propellant complexity.

A new dosage form would require a separate regulatory and clinical strategy. It would not automatically qualify as an equivalent version of the Azelex cream. The product sponsor would need to establish the appropriate FDA pathway, including whether the dosage form can be supported through an ANDA or requires a 505(b)(2) application.

Preservative-free and airless packaging

A preservative-reduced or preservative-free product could target patients with sensitive skin. Airless pumps, unit-dose packages and laminated tubes may reduce contamination risk and improve dose consistency.

Packaging can also create commercial differentiation without changing the active ingredient. The tradeoff is higher component cost, more complex compatibility testing and potential supply-chain constraints.

What formulation patents could protect a new Azelex competitor?

A new azelaic acid product could seek patent protection around:

• Specific azelaic acid particle-size ranges.
• Stable high-concentration suspensions.
• Defined oil-to-water ratios.
• Novel emulsifier combinations.
• Low-irritation preservative systems.
• Controlled-release topical vehicles.
• Improved skin deposition or penetration.
• Foam or emulgel delivery systems.
• Airless packaging combined with a preservative-free composition.
• Treatment of acne, rosacea or hyperpigmentation using a defined formulation.

Patent value will depend on claim breadth and design-around difficulty. A narrow claim covering a particular excipient ratio may be easy to avoid. A broader claim tied to measurable performance, such as stability, particle distribution or deposition, may have greater defensive value if the specification supports it.

What FDA regulatory pathway applies to an Azelex generic?

A conventional azelaic acid 20% cream may be eligible for an ANDA referencing Azelex, subject to FDA requirements for pharmaceutical equivalence and bioequivalence.[3,5]

Topical products can require more than simple active-ingredient matching. FDA may assess:

• Same dosage form and strength.
• Same route of administration.
• Q1 qualitative sameness of inactive ingredients where required.
• Q2 quantitative sameness or justified differences.
• Comparative physicochemical characterization.
• In vitro release testing.
• In vitro permeation testing.
• Product performance and rheology.
• Microbiological quality.
• Comparative clinical endpoint studies when necessary.

A materially different vehicle may require a 505(b)(2) application rather than an ANDA. That route can support a differentiated formulation but usually involves greater development cost and a more extensive regulatory package.

What generic entry risks exist for Azelex?

Generic entry risk is high at the active-ingredient level because azelaic acid is old and widely available. The principal barriers are technical and commercial:

Risk factor	Impact
Low formulation complexity	Encourages multiple generic entrants
High active loading	Increases scale-up and uniformity risk
Topical bioequivalence	Can extend development timelines
Low brand differentiation	Creates price pressure
Dermatology prescribing habits	May support limited brand loyalty
Cosmetic azelaic acid products	Expands consumer competition
Sensitive-skin tolerability	Creates opportunity for differentiated products

A conventional generic may face rapid price erosion if several suppliers enter. A branded-generic strategy based on better tolerability, packaging, patient support or physician education could preserve margin.

How does Azelex compare with competing azelaic acid products?

Product type	Typical strength	Positioning	Commercial advantage
Azelex cream	20%	Prescription acne treatment	Established FDA-approved reference product
Generic azelaic acid cream	20%	Lower-cost prescription substitute	Price and pharmacy access
Azelaic acid gel products	Commonly 15%	Often associated with rosacea treatment	Lighter vehicle and different indication
Nonprescription cosmetic products	Variable	Hyperpigmentation, acne and skin tone	Direct consumer access
Compounded formulations	Variable	Individualized dermatology use	Customization and vehicle flexibility

Azelex competes against both FDA-approved prescription products and consumer products that use azelaic acid at lower or variable concentrations. Its strongest defensible position is prescription status, standardized concentration and physician familiarity.

What licensing and commercial opportunities exist?

Licensing opportunities are more likely to involve formulation technology than the Azelex brand itself. Relevant assets include:

• Micronized azelaic acid platforms.
• Low-irritation preservative systems.
• Novel topical emulsions.
• Airless and unit-dose delivery systems.
• Combination products with niacinamide, retinoids or anti-inflammatory agents.
• Dermatology-focused contract manufacturing capacity.
• Geographic rights for branded-generic distribution.

Potential licensees include dermatology companies, generic manufacturers, specialty pharmacies and consumer health companies seeking prescription-to-OTC lifecycle extensions.

A combination product could have commercial value, but it would face additional compatibility, stability, safety and regulatory requirements. Combining azelaic acid with a retinoid or antimicrobial may improve clinical positioning but would also raise irritation and development risks.

What are the revenue and market opportunities for Azelex?

Azelex-specific revenue is generally not disclosed separately by public companies. The product should therefore be valued using market share, prescription volume, net price and channel assumptions rather than reported brand revenue.

Commercial opportunities include:

1. A low-cost generic 20% cream with reliable pharmacy supply.
2. A premium branded generic with improved sensory characteristics.
3. A 505(b)(2) gel, foam or emulgel.
4. A sensitive-skin formulation with reduced preservative burden.
5. An expanded dermatology platform targeting acne, rosacea and hyperpigmentation.
6. International licensing where azelaic acid prescription competition is less developed.
7. Direct-to-consumer education around treatment adherence and irritation management.

The greatest near-term opportunity is a differentiated topical vehicle. The greatest volume opportunity is a conventional generic, but that segment is likely to experience rapid competition and limited pricing power.

Key Takeaways

• Azelex is a 20% azelaic acid prescription cream approved for mild-to-moderate inflammatory acne vulgaris.
• Its excipient system uses a conventional emulsion architecture with glycerin, glyceryl stearate, isopropyl myristate, polyethylene glycol, stearyl alcohol, benzoic acid and purified water.
• Regulatory exclusivity has expired, making generic entry primarily a formulation, bioequivalence and commercial execution issue.
• Patent value is more likely to reside in formulation, particle-size, manufacturing or delivery claims than in azelaic acid itself.
• Azelex’s principal commercial vulnerabilities are irritation, sensory limitations, low molecule-level differentiation and generic price competition.
• The strongest product opportunities involve low-irritation vehicles, improved particle control, airless packaging, gel or emulgel delivery, and branded-generic positioning.
• A conventional 20% cream is likely to face high generic entry risk, while a materially improved vehicle may support a 505(b)(2) strategy and stronger commercial differentiation.

FAQs

Can a generic Azelex product use different excipients?

Yes. An ANDA product may contain different inactive ingredients if the differences are permitted under FDA requirements and do not affect safety, performance or bioequivalence. Q1 and Q2 sameness requirements must be assessed for the specific product and regulatory pathway.

Is azelaic acid protected by a composition-of-matter patent?

Azelaic acid is an established chemical entity, so current commercial protection is unlikely to depend on a basic composition-of-matter patent. Relevant protection would more likely involve a specific formulation, use, process or delivery system.

Could a foam version of Azelex receive separate patent protection?

Yes. A foam formulation could be protected through claims directed to composition, particle size, propellant system, stabilization, packaging, skin deposition or a defined therapeutic use. Patent strength would depend on claim scope and the ability of competitors to design around it.

Is Azelex suitable for an OTC switch?

Potentially, but an OTC switch would require FDA review of consumer labeling, safe self-selection, directions, duration of use and the ability of consumers to diagnose and treat the labeled condition without professional supervision. The switch would require a separate regulatory strategy.

Does a better excipient system create automatic market exclusivity?

No. Improved excipients can support patent protection, trade-secret manufacturing advantages, better product performance or premium positioning, but they do not automatically create regulatory exclusivity or prevent generic competition.

References

1. U.S. Food and Drug Administration. (2024). Azelex: Azelaic acid cream, 20% prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
3. U.S. Food and Drug Administration. (2023). Approved drug products and patent and exclusivity information. Drugs@FDA.
4. National Library of Medicine. (2024). DailyMed: Azelex azelaic acid cream.
5. U.S. Food and Drug Administration. (2022). Product-specific guidance for azelaic acid topical products. FDA.